Peter Edward Fecci

Neurosurgery

Professor of Neurosurgery

Peter Edward Fecci Profile Photo

Research Interests

Brain Tumor Immunotherapy
Cancer-Induced Immune Dysfunction
Glioblastoma
Brain Metastasis

Bio

As the Director of both the Brain Tumor Immunotherapy Program and the Center for Brain and Spine Metastasis at Duke University, I focus our programmatic interests on the design, optimization, and monitoring of immune-based treatment platforms for patients with intracranial tumors, whether primary or metastatic. Within this broad scope, however, my own group looks more specifically at limitations to immunotherapeutic success, with a particular focus on understanding and reversing T cell dysfunction in patients with glioblastoma (GBM) and brain metastases. We employ a systematic approach to categorizing T cell dysfunction (Woroniecka et al, Clin Cancer Res 2018 Aug 15;24(16):3792-3802), and whereas our earlier work addressed concerns for regulatory T cell-induced tolerance, we now heavily study T cell ignorance and exhaustion, as well. Regarding the former, we recently published the novel phenomenon of S1P1-mediated bone marrow T cell sequestration in patients with intracranial tumors (Chongsathidkiet et al, Nat Medicine 2018 Sep;24(9):1459-1468). Regarding the latter, we have likewise recently identified and characterized exhaustion as a significant limitation to T-cell function within GBM (Woroniecka et al, Clin Cancer Res 2018 Sep 1;24(17):4175-4186). I very much look to collaboratively integrate our approaches with others investigating innovative treatment options. I continue my focus on combining strategies for reversing T cell deficits with current and novel immune-based platforms as a means of deriving and improving rational and precise anti-tumor therapies. It is my sincerest desire to forge a career focused on co-operative, multi-disciplinary, organized brain tumor therapy. Ultimately, my goal is to help coordinate the efforts of a streamlined and effective center for brain tumor research and clinical care. I hope to play some role in ushering in a period where the science and treatment arms of brain tumor therapy suffer no disjoint, but instead represent the convergent efforts of researchers, neuro-oncologists, medical oncologists, radiation oncologists, biomedical engineers, and neurosurgeons alike. I hope to see such synergy become standard of care.

Education

M.D. Duke University, School of Medicine, 2007
Ph.D. Duke University, 2007

Trainings & Certifications

Internship, GENERAL SURGERY (2007 - 2008) Massachusetts General Hospital
Residency, NEUROSURGERY (2008 - 2013) Massachusetts General Hospital
Postdoctoral Fellow (2010 - 2012) Dana Farber Cancer Institute

Positions

Professor of Neurosurgery
Professor in Pathology
Associate Professor of Biomedical Engineering
Associate Professor in Integrative Immunobiology
Member of the Duke Cancer Institute

Awards, Honors, and Distinctions

Visting Scholar. National Institutes of Health. 2017
Paper of the Year. American Association of Physicists in Medicine. 2017
Prince Mahidol Youth Mentor Award. Prince Mahidol Award Foundation. 2016
Duke Health Scholars Award. Duke University School of Medicine. 2016
Sontag Distinguished Scientist Award. Sontag Foundation. 2015
Alpha Omega Alpha. Alpha Omega Alpha Medical Honor Society. 2015
Resident Advocate Award. Duke University Department of Neurosurgery. 2015
Matson Award for Best Basic Science Research. New England Neurosurgical Society. 2013
Preuss Award for Neuro-Oncologic Research. Congress of Neurological Surgeons. 2013
NIH Loan Repayment Program Award. National Institutes of Health. 2011
Resident Teaching Award. Tufts University School of Medicine. 2008
Neurosurgery Award. Duke University Department of Neurosurgery. 2007
Keynote Speaker. Society for Neuro-Oncology. 2006
Medical Scientist Training Program Fellowship. National Institutes of Health. 2001
Eugene A. Stead Scholar. Duke University School of Medicine. 2001
Merrill Presidential Scholar. Cornell University. 1999
Cornell-Diamante Scholarship. Cornell University. 1999
Nanaline H. Duke Scholar. Duke University School of Medicine. 1999

Courses Taught

PATHOL 793: Research Independent Study
PATHOL 293: Research Independent Study
NEUROSCI 494: Research Independent Study 2
NEUROSCI 493: Research Independent Study 1
MOLMED 301B: Research in MOLMED - Oncological Sciences

Publications

Zhao J, Vaios E, Wang Y, Yang Z, Cui Y, Reitman ZJ, et al. Dose-Incorporated Deep Ensemble Learning for Improving Brain Metastasis Stereotactic Radiosurgery Outcome Prediction. Int J Radiat Oncol Biol Phys. 2024 Oct 1;120(2):603–13.
Hotchkiss KM, Karschnia P, Schreck KC, Geurts M, Cloughesy TF, Huse J, et al. A brave new framework for glioma drug development. Lancet Oncol. 2024 Oct;25(10):e512–9.
Chiang VL, Pugazenthi S, Leidig WA, Rodriguez A, Prabhu S, Haskell-Mendoza AP, et al. Laser interstitial thermal therapy for new and recurrent meningioma: a prospective and retrospective case series. J Neurosurg. 2024 Sep 1;141(3):642–52.
Sperber J, Yoo S, Owolo E, Dalton T, Zachem TJ, Johnson E, et al. Validation of the graded prognostic assessment and recursive partitioning analysis as prognostic tools using a modern cohort of patients with brain metastases. Neuro-Oncology Practice. 2024 Jun 24;
Whiteley AE, Ma D, Wang L, Yu S-Y, Yin C, Price TT, et al. Breast cancer exploits neural signaling pathways for bone-to-meninges metastasis. Science. 2024 Jun 21;384(6702):eadh5548.
Haskell-Mendoza AP, Srinivasan ES, Vo-Dinh T, Fecci PE. Leveraging gold nanostars for precision laser interstitial thermal therapy. Oncotarget. 2024 Jun 14;15:389–91.
Haskell-Mendoza AP, Reason EH, Gonzalez AT, Jackson JD, Sankey EW, Srinivasan ES, et al. Automated segmentation of ablated lesions using deep convolutional neural networks: A basis for response assessment following laser interstitial thermal therapy. Neuro Oncol. 2024 Jun 3;26(6):1152–62.
Leng JX, Carpenter DJ, Huang C, Qazi J, Arshad M, Mullikin TC, et al. Determinants of Symptomatic Intracranial Progression After an Initial Stereotactic Radiosurgery Course. Adv Radiat Oncol. 2024 Jun;9(6):101475.
Neff C, Price M, Cioffi G, Liu Z, Walsh R, Barnholtz-Sloan JS, et al. Atopy improves survival and decreases risk of brain metastasis in cutaneous melanoma. 2024.
Fairchild A, Salama JK, Godfrey D, Wiggins WF, Ackerson BG, Oyekunle T, et al. Incidence and imaging characteristics of difficult to detect retrospectively identified brain metastases in patients receiving repeat courses of stereotactic radiosurgery. J Neurooncol. 2024 Mar;167(1):219–27.
Haskell-Mendoza AP, Radhakrishnan S, Nardin AL, Eilbacher K, Yang LZ, Jackson JD, et al. Utility of Routine Preoperative Urinalysis in the Prevention of Surgical Site Infections. World Neurosurg. 2023 Dec;180:e449–59.
Saatian B, Deshpande K, Herrera R, Sedighi S, Eisenbarth R, Iyer M, et al. Breast-to-brain metastasis is exacerbated with chemotherapy through blood-cerebrospinal fluid barrier and induces Alzheimer's-like pathology. J Neurosci Res. 2023 Dec;101(12):1900–13.
Singh K, Hotchkiss KM, Parney IF, De Groot J, Sahebjam S, Sanai N, et al. Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. Nat Med. 2023 Oct;29(10):2402–5.
Lerner EC, Woroniecka KI, D’Anniballe VM, Wilkinson DS, Mohan AA, Lorrey SJ, et al. CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis. Nat Cancer. 2023 Sep;4(9):1258–72.
Srinivasan ES, Liu Y, Odion RA, Chongsathidkiet P, Wachsmuth LP, Haskell-Mendoza AP, et al. Gold Nanostars Obviate Limitations to Laser Interstitial Thermal Therapy (LITT) for the Treatment of Intracranial Tumors. Clin Cancer Res. 2023 Aug 15;29(16):3214–24.
Haskell-Mendoza AP, Srinivasan ES, Lerner EC, Edwards RM, Schwalb AM, Jackson JD, et al. Risk of Tract Seeding Following Laser Interstitial Thermal Therapy for Brain Tumors. Neurosurgery. 2023 Jul 1;93(1):198–205.
Fairchild AT, Salama JK, Wiggins WF, Ackerson BG, Fecci PE, Kirkpatrick JP, et al. A Deep Learning-Based Computer Aided Detection (CAD) System for Difficult-to-Detect Brain Metastases. Int J Radiat Oncol Biol Phys. 2023 Mar 1;115(3):779–93.
McCray E, Waguia R, de la Garza Ramos R, Price MJ, Williamson T, Dalton T, et al. Racial disparities in inpatient clinical presentation, treatment, and outcomes in brain metastasis. Neurooncol Pract. 2023 Feb;10(1):62–70.
Haskell-Mendoza AP, Srinivasan ES, Suarez AD, Fecci PE. Laser ablation of a sphenoid wing meningioma: A case report and review of the literature. Surg Neurol Int. 2023;14:138.
Chan M, Tatter S, Chiang V, Fecci P, Strowd R, Prabhu S, et al. Efficacy of laser interstitial thermal therapy for biopsy-proven radiation necrosis in radiographically recurrent brain metastases. Neurooncol Adv. 2023;5(1):vdad031.
Wilson Z, Fecci P. T CELL SEQUESTRATION IN POSTERIOR FOSSA TUMORS. In: NEURO-ONCOLOGY. 2023.
Koga SF, Hodges WB, Adamyan H, Hayes T, Fecci PE, Tsvankin V, et al. Preoperative validation of edema-corrected tractography in neurosurgical practice: translating surgeon insights into novel software implementation. Front Neurol. 2023;14:1322815.
Lorrey SJ, Waibl Polania J, Wachsmuth LP, Hoyt-Miggelbrink A, Tritz ZP, Edwards R, et al. Systemic immune derangements are shared across various CNS pathologies and reflect novel mechanisms of immune privilege. Neurooncol Adv. 2023;5(1):vdad035.
Carpenter DJ, Fairchild AT, Adamson JD, Fecci PE, Sampson JH, Herndon JE, et al. Outcomes in Patients with Intact and Resected Brain Metastasis Treated with 5-Fraction Stereotactic Radiosurgery. Adv Radiat Oncol. 2023;8(2):101166.
Lerner EC, Srinivasan ES, Broadwater G, Haskell-Mendoza AP, Vaios EJ, Edwards RM, et al. Erratum to "E.C. Lerner, E.S. Srinivasan, G. Broadwater, et al. Factors Associated With New-Onset Seizures Following Stereotactic Radiosurgery for Newly Diagnosed Brain Metastases. Adv Radiat Oncol. 2022;7:101054.". Adv Radiat Oncol. 2023;8(2):101187.
Lerner E, Woroniecka K, D’Anniballe V, Wilkinson D, Lorrey S, Waibl-Polania J, et al. A Novel MHC-Independent Mechanism of Tumor Cell Killing by CD8⁺T Cells. bioRxiv. 2023.
Waibl Polania J, Hoyt-Miggelbrink A, Tomaszewski W, Wachsmuth L, Lorrey S, Wilkinson D, et al. Antigen presentation by tumor-associated macrophages mediates progenitor to terminal exhaustion transition in GBM and other solid tumors. bioRxiv. 2023.
Schwalb AM, Srinivasan ES, Fecci PE. Commentary: Laser Interstitial Thermal Therapy for First-Line Treatment of Surgically Accessible Recurrent Glioblastoma: Outcomes Compared With a Surgical Cohort. Neurosurgery. 2022 Dec 1;91(6):e160–3.
Tomaszewski WH, Waibl-Polania J, Chakraborty M, Perera J, Ratiu J, Miggelbrink A, et al. Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma. Nat Commun. 2022 Oct 29;13(1):6483.
Carpenter DJ, Natarajan B, Arshad M, Natesan D, Schultz O, Moravan MJ, et al. Prognostic Model for Intracranial Progression after Stereotactic Radiosurgery: A Multicenter Validation Study. Cancers (Basel). 2022 Oct 22;14(21).
Lerner EC, Edwards RM, Wilkinson DS, Fecci PE. Laser ablation: Heating up the anti-tumor response in the intracranial compartment. Adv Drug Deliv Rev. 2022 Jun;185:114311.
Sankey EW, Grabowski MM, Srinivasan ES, Griffin AS, Howell EP, Otvos B, et al. Time to Steroid Independence After Laser Interstitial Thermal Therapy vs Medical Management for Treatment of Biopsy-Proven Radiation Necrosis Secondary to Stereotactic Radiosurgery for Brain Metastasis. Neurosurgery. 2022 Jun 1;90(6):684–90.
Lerner EC, Tomaszewski W, D’Anniballe V, Perera J, Cui X, Wilkinson DS, et al. CD8 T cells licensed with immune checkpoint blockade kill murine tumors lacking MHC-I. In: The Journal of Immunology. The American Association of Immunologists; 2022. p. 121.14-121.14.
Wilkinson DS, Ryan K, Wilson J, Chandramohan V, Landi D, Bigner D, et al. D2C7 CAR: A novel CAR T cell that simultaneously targets wildtype EGFR and its mutant isoform EGFRvIII for treatment of glioma. In: The Journal of Immunology. The American Association of Immunologists; 2022. p. 122.03-122.03.
Bramall AN, Anton ES, Kahle KT, Fecci PE. Navigating the ventricles: Novel insights into the pathogenesis of hydrocephalus. EBioMedicine. 2022 Apr;78:103931.
Flores C, Dunn G, Fecci P, Lim M, Mitchell D, Reardon DA. Is There a Role for Immunotherapy in Central Nervous System Cancers? Hematol Oncol Clin North Am. 2022 Feb;36(1):237–52.
Fairchild A, Salama JK, Godfrey DJ, Wiggins W, Ackerson B, Niedzwiecki D, et al. Early Imaging Characteristics Associated with Development of Future Brain Metastases in Patients Undergoing Stereotactic Radiosurgery. In: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2022. p. E51–E51.
de Groot J, Kim A, Prabhu S, Rao G, Laxton A, Fecci P, et al. EFFICACY OF LASER INTERSTITIAL THERMAL THERAPY (LITT) FOR NEWLY DIAGNOSED AND RECURRENT IDH WILD-TYPE GLIOBLASTOMA. In: NEURO-ONCOLOGY. 2022. p. 256–7.
Fecci PE, Rao G, Brastianos PK, Dunn GP, Anders CK. Editorial: It takes a village: The expanding multi-disciplinary approach to brain metastasis. Front Oncol. 2022;12:1054490.
Tucker M, Lacayo M, Joseph S, Ross W, Chongsathidkiet P, Fecci P, et al. Creation of Non-Contact Device for Use in Metastatic Melanoma Margin Identification in ex vivo Mouse Brain. Proc SPIE Int Soc Opt Eng. 2022;11945.
Grabowski MM, Srinivasan ES, Vaios EJ, Sankey EW, Otvos B, Krivosheya D, et al. Combination laser interstitial thermal therapy plus stereotactic radiotherapy increases time to progression for biopsy-proven recurrent brain metastases. Neurooncol Adv. 2022;4(1):vdac086.
Lerner EC, Srinivasan ES, Broadwater G, Haskell-Mendoza AP, Edwards RM, Huie D, et al. Factors Associated With New-Onset Seizures Following Stereotactic Radiosurgery for Newly Diagnosed Brain Metastases. In: Adv Radiat Oncol. 2022. p. 101054.
Peña Pino I, Ma J, Hori YS, Fomchenko E, Dusenbery K, Reynolds M, et al. Stereotactic Laser Ablation (SLA) followed by consolidation stereotactic radiosurgery (cSRS) as treatment for brain metastasis that recurred locally after initial radiosurgery (BMRS): a multi-institutional experience. J Neurooncol. 2022 Jan;156(2):295–306.
Carpenter DJ, Fairchild A, Adamson J, Moravan MJJ, Fecci P, Herndon J, et al. Outcomes in Intact and Resected Brain Metastasis Patients Treated with Five-Fraction Stereotactic Radiosurgery. In: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2022. p. E49–50.
Lerner E, D’Anniballe V, Tomaszewski W, Perera J, Cui X, Waibl-Polania J, et al. CD8 T cell mediated killing of MHC class 1 negative tumors requires antigen presenting myeloid cells and interferon gamma. In: CANCER RESEARCH. 2022.
Neman J, Saatian B, Deshpande K, Martisorian V, LaViolette P, Boire A, et al. BREAST TO BRAIN METASTASIS IS EXACERBATED WITH CHEMOTHERAPY THROUGH BLOOD-CEREBRAL SPINAL FLUID-BARRIER AND INDUCES ALZHEIMER'S-LIKE PATHOLOGY. In: NEURO-ONCOLOGY. 2022. p. 21–2.
Zhao J, Vaios EJ, Carpenter DJ, Yang Z, Cui Y, Lafata K, et al. A Radiomics-Integrated Deep Learning Model for Identifying Radionecrosis Following Brain Metastasis Stereotactic Radiosurgery (SRS). In: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2022. p. S114–S114.
Singh K, Foster M, Miller ES, Gregory S, Weinhold KJ, Ashley DM, et al. A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma. In: JOURNAL OF CLINICAL ONCOLOGY. 2022. p. TPS2076–TPS2076.
Wilson J, Wilkinson D, Ryan K, Bigner D, Chambramohan V, Fecci P. A NOVEL DUAL-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL WITH HIGH SPECIFICITY FOR EGFR AND EGFRVIII IMPROVES SURVIVAL IN EGFR EXPRESSING MEDULLOBLASTOMA. In: NEURO-ONCOLOGY. 2022. p. 228–9.
Fairchild A, Salama JK, Wiggins W, Ackerson B, Fecci P, Kirkpatrick JP, et al. A Deep Learning-Based Computer Aided Detection (CAD) System for Difficult-to-Detect Brain Metastases (BM). In: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2022. p. S111–2.
Huie D, Lerner EC, Edwards RM, Srinivasan ES, Vaios EJ, Fecci PE. Advanced imaging techniques and planning for laser interstitial thermal therapy. In: Handbook of Neuro-Oncology Neuroimaging. 2022. p. 285–301.
de Groot JF, Kim AH, Prabhu S, Rao G, Laxton AW, Fecci PE, et al. Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma. Neurooncol Adv. 2022;4(1):vdac040.
Tomaszewski WH, Waibl-Polania J, Miggelbrink AM, Chakraborty MA, Fecci PE, Sampson JH, et al. Broad immunophenotyping of the murine brain tumor microenvironment. J Immunol Methods. 2021 Dec;499:113158.
Batich K, Mitchell D, Healy P, Herndon J, Broadwater G, Michael G, et al. CTIM-10. REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA. In: Neuro-Oncology. Oxford University Press (OUP); 2021. p. vi51–vi51.
Miggelbrink AM, Jackson JD, Lorrey SJ, Srinivasan ES, Waibl-Polania J, Wilkinson DS, et al. CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer? Clin Cancer Res. 2021 Nov 1;27(21):5742–52.
Srinivasan ES, Grabowski MM, Nahed BV, Barnett GH, Fecci PE. Laser interstitial thermal therapy for brain metastases. Neurooncol Adv. 2021 Nov;3(Suppl 5):v16–25.
Vaios EJ, Grabowski M, Srinivasan E, Huie D, Sankey E, Otvos B, et al. Combining Laser Interstitial Thermal Therapy With SRS Improves Time to Progression for Recurrent SRS-Treated Brain Metastases. In: International journal of radiation oncology, biology, physics. 2021. p. e583–4.
Kang JH, Price M, Dalton T, Ramirez L, Fecci PE, Kamal AH, et al. Palliative Care Use for Critically Ill Patients With Brain Metastases. J Pain Symptom Manage. 2021 Nov;62(5):927–35.
Chongsathidkiet P, Fecci PE. Cold-inducible RNA-binding protein (CIRBP) as a biomarker to predict recurrence of brain metastases. Neuro Oncol. 2021 Sep 1;23(9):1419–20.
Price M, Howell EP, Dalton T, Ramirez L, Howell C, Williamson T, et al. Inpatient palliative care utilization for patients with brain metastases. Neurooncol Pract. 2021 Aug;8(4):441–50.
Nduom EK, Gephart MH, Chheda MG, Suva ML, Amankulor N, Battiste JD, et al. Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators. Neurosurgery. 2021 Jun 15;89(1):129–32.
Srinivasan ES, Tsvankin V, Fecci PE. Commentary: A Neurosurgeon's Guide to Cognitive Dysfunction in Adult Glioma. Neurosurgery. 2021 Jun 15;89(1):E1–2.
Otvos B, Alban TJ, Grabowski MM, Bayik D, Mulkearns-Hubert EE, Radivoyevitch T, et al. Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome. Clin Cancer Res. 2021 Apr 1;27(7):2038–49.
Chuntova P, Chow F, Watchmaker PB, Galvez M, Heimberger AB, Newell EW, et al. Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro Oncol. 2021 Mar 25;23(3):356–75.
Srinivasan ES, Tan AC, Anders CK, Pendergast AM, Sipkins DA, Ashley DM, et al. Salting the Soil: Targeting the Microenvironment of Brain Metastases. Mol Cancer Ther. 2021 Mar;20(3):455–66.
Price LS, Adamow M, Attig S, Fecci P, Norberg P, Reap E, et al. Gating Harmonization Guidelines for Intracellular Cytokine Staining Validated in Second International Multiconsortia Proficiency Panel Conducted by Cancer Immunotherapy Consortium (CIC/CRI). Cytometry A. 2021 Jan;99(1):107–16.
Srinivasan E, Chongsathidkiet P, Odion R, Liu Y, Sankey E, Vo-Dinh T, et al. INTEGRATION OF PLASMONIC GOLD NANOSTARS AND LASER INTERSTITIAL THERMAL THERAPY (LITT) FOR SPECIFIC AND AMPLIFIED ABLATION OF BRAIN TUMORS. In: NEURO-ONCOLOGY. 2021. p. 167–167.
Kim AH, Tatter S, Rao G, Prabhu S, Chen C, Fecci P, et al. Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation. In: NEUROSURGERY. 2021. p. S16–S16.
Polania JW, Tomaszweski W, Hoyt-Miggelbrink A, Woroniecka K, Fecci P. INVESTIGATING CD8 T CELL EXHAUSTION STATES GLIOBLASTOMA. In: NEURO-ONCOLOGY. 2021. p. 95–95.
Liu Y, Chongsathidkiet P, Odion R, Fecci PE, Vo-Dinh T. Multifunctional Gold Nanostars for Sensitive Detection, Photothermal Treatment and Immunotherapy of Brain Tumor. In: Bioanalysis. Springer International Publishing; 2021. p. 235–55.
Batich K, Mitchell D, Healy P, Herndon J, Broadwater G, Michael G, et al. REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA. In: NEURO-ONCOLOGY. 2021. p. 51–51.
Wilkinson D, Ryan K, Chandramohan V, Landi D, Bigner D, Fecci P. GENERATION OF A THIRD GENERATION CAR T CELL THAT SIMULTANEOUSLY TARGETS WILDTYPE EGFR AND ITS MUTANT ISOFORM EGFRVIII FOR TREATMENT OF GLIOBLASTOMA. In: NEURO-ONCOLOGY. 2021. p. 176–176.
Grabowski MM, Sankey EW, Ryan KJ, Chongsathidkiet P, Lorrey SJ, Wilkinson DS, et al. Immune suppression in gliomas. J Neurooncol. 2021 Jan;151(1):3–12.
Waibl Polania J, Lerner EC, Wilkinson DS, Hoyt-Miggelbrink A, Fecci PE. Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies. Front Immunol. 2021;12:777073.
Medikonda R, Dunn G, Rahman M, Fecci P, Lim M. A review of glioblastoma immunotherapy. J Neurooncol. 2021 Jan;151(1):41–53.
Mohan AA, Tomaszewski WH, Haskell-Mendoza AP, Hotchkiss KM, Singh K, Reedy JL, et al. Targeting Immunometabolism in Glioblastoma. Front Oncol. 2021;11:696402.
Shen E, Van Swearingen AED, Price MJ, Bulsara K, Verhaak RGW, Baëta C, et al. A Need for More Molecular Profiling in Brain Metastases. Front Oncol. 2021;11:785064.
Srinivasan E, Lerner E, Edwards R, Huie D, Fecci P. FUNCTIONAL OUTCOMES OF LASER INTERSTITIAL THERMAL THERAPY (LITT) VERSUS RESECTION IN THE TREATMENT OF LESIONS IN OR NEAR THE PRIMARY MOTOR CORTEX. In: NEURO-ONCOLOGY. 2021. p. 195–195.
Chongsathidkiet P, Waibl Polania J, Lorrey SJ, Grabowski MM, Sankey EW, Wilkinson DS, et al. Cancer Immunotherapy Strategies: Basic Principles. In: Bioanalysis. Springer International Publishing; 2021. p. 29–49.
Polania JW, Lorrey S, Wilkinson D, Fecci PE. Immune checkpoint blockade therapy in high-grade glioma. In: Immunotherapeutic Strategies for the Treatment of Glioma. 2021. p. 91–108.
Kim GJ, Buckley ED, Herndon JE, Allen KJ, Dale TS, Adamson JD, et al. Outcomes in Patients With 4 to 10 Brain Metastases Treated With Dose-Adapted Single-Isocenter Multitarget Stereotactic Radiosurgery: A Prospective Study. Adv Radiat Oncol. 2021;6(6):100760.
Adil SM, Hodges SE, Edwards RM, Charalambous LT, Yang Z, Kiyani M, et al. Health care resource utilization and treatment of leptomeningeal carcinomatosis in the United States. Neurooncol Pract. 2020 Dec;7(6):636–45.
Sankey EW, Srinivasan ES, Mehta VA, Bergin SM, Wang TY, Thompson EM, et al. Perioperative Assessment of Cerebellar Masses and the Potential for Cerebellar Cognitive Affective Syndrome. World Neurosurg. 2020 Dec;144:222–30.
Landazuri P, Shih J, Leuthardt E, Ben-Haim S, Neimat J, Tovar-Spinoza Z, et al. A prospective multicenter study of laser ablation for drug resistant epilepsy - One year outcomes. Epilepsy Res. 2020 Nov;167:106473.
Gastman B, Agarwal PK, Berger A, Boland G, Broderick S, Butterfield LH, et al. Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. J Immunother Cancer. 2020 Nov;8(2).
Woroniecka K, Fecci PE. Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma. Neuro Oncol. 2020 Sep 29;22(9):1233–4.
Kim AH, Tatter S, Rao G, Prabhu S, Chen C, Fecci P, et al. Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation. Neurosurgery. 2020 Sep 1;87(3):E338–46.
Liu Y, Maccarini P, Palmer GM, Inman BA, Fecci PE, Vo-Dinh T. Abstract 6630: Synergistic immuno photothermal nanotherapy (SYMPHONY) for combination cancer therapy. In: Cancer Research. American Association for Cancer Research (AACR); 2020. p. 6630–6630.
Srinivasan ES, Sankey EW, Grabowski MM, Chongsathidkiet P, Fecci PE. The intersection between immunotherapy and laser interstitial thermal therapy: a multipronged future of neuro-oncology. Int J Hyperthermia. 2020 Jul;37(2):27–34.
Shen SH, Woroniecka K, Barbour AB, Fecci PE, Sanchez-Perez L, Sampson JH. CAR T cells and checkpoint inhibition for the treatment of glioblastoma. Expert Opin Biol Ther. 2020 Jun;20(6):579–91.
Rennert RC, Khan U, Bartek J, Tatter SB, Field M, Toyota B, et al. Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization. Neurosurgery. 2020 Apr 1;86(4):538–47.
Moravan MJ, Fecci PE, Anders CK, Clarke JM, Salama AKS, Adamson JD, et al. Current multidisciplinary management of brain metastases. Cancer. 2020 Apr 1;126(7):1390–406.
Grabowski MM, Sankey E, Srinivasan E, Howell E, Scott A, Olufawo M, et al. Laser Interstitial Thermal Therapy Followed By SRS Increases Time to Progression of Recurrent Brain Metastases Initially Treated With SRS. In: JOURNAL OF NEUROSURGERY. AMER ASSOC NEUROLOGICAL SURGEONS; 2020. p. 111–111.
Woroniecka KI, Rhodin KE, Dechant C, Cui X, Chongsathidkiet P, Wilkinson D, et al. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers. Clin Cancer Res. 2020 Mar 15;26(6):1349–58.
Kemeny HR, Elsamadicy AA, Farber SH, Champion CD, Lorrey SJ, Chongsathidkiet P, et al. Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. Clin Cancer Res. 2020 Mar 1;26(5):1141–51.
Huang M-N, Nicholson LT, Batich KA, Swartz AM, Kopin D, Wellford S, et al. Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses. J Clin Invest. 2020 Feb 3;130(2):774–88.
Polania JW, Woroniecka K, Sanchez-Perez L, Fecci P. Antigen-presenting cells lead to severe T cell exhaustion in glioblastoma. In: JOURNAL OF IMMUNOLOGY. 2020.
Otvos B, Alban T, Grabowski M, Bayik D, Winkelman R, Johnson S, et al. MODELING UPFRONT GLIOBLASTOMA SURGICAL RESECTION AND STEROID USE REVEALS IMMUNOSUPPRESSIVE CHANGES AND SUGGESTS THAT PERIPHERAL LYMPHOCYTE COUNTS ARE ASSOCIATED WITH TUMOR VOLUME AND PROGNOSIS. In: NEURO-ONCOLOGY. 2020. p. 106–106.
Cupil-Garcia V, Liu Y, Crawford BM, Chongsathidkiet P, Palmer G, Maccarini P, et al. Nanostar probes: A golden platform for Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) for the treatment of metastatic cancer. In: Progress in Biomedical Optics and Imaging - Proceedings of SPIE. 2020.
Kirkpatrick JP, Crapo J, Floyd SR, Torok JAJ, Franklin H, Anders CK, et al. Preserving Neurocognition Without Compromising Tumor Control During Whole-Brain Radiotherapy Therapy In Patients With Numerous Brain Metastases Via A Novel Superoxide Dismutase Mimetic: Initial Safety Lead-In And Design Of A Clinical Trial. In: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2020. p. E719–E719.
Sankey EW, Grabowski MM, Srinavasan E, Griffin A, Howell EP, Otvos B, et al. Faster Steroid Cessation After Laser Interstitial Thermal Therapy Versus Medical Management in Biopsy-Proven Radiation Necrosis After Stereotactic Radiosurgery for Brain Metastasis: A Multicenter Retrospective Cohort Review. In: NEUROSURGERY. 2020. p. 314–5.
Grabowski MM, Sankey EW, Srinivasan E, Griffin A, Otvos B, Olufawo M, et al. Combination Laser Interstitial Thermal Therapy Plus SRS Increases Time to Progression for Recurrent SRS-Treated Brain Metastases. In: NEUROSURGERY. 2020. p. 285–6.
Kim GJ, Buckley ED, Herndon J, Allen KJ, Dale T, Adamson J, et al. Outcomes In Patients With 4-10 Brain Metastases Treated With Dose-Adapted Single-Isocenter Multitarget Stereotactic Radiosurgery: A Prospective Study. In: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2020. p. E727–8.
Grabowski M, Sankey E, Srinivasan E, Otvos B, Scott A, Olufawo M, et al. COMBINATION LASER INTERSTITIAL THERMAL THERAPY PLUS SRS INCREASES TIME TO PROGRESSION FOR RECURRENT SRS-TREATED BRAIN METASTASES. In: NEURO-ONCOLOGY. 2020. p. 203–203.
Wilkinson DS, Champion C, Chongsathidkiet P, Wang H, Laskowitz D, Fecci P. Bone marrow T cell sequestration as a novel mode of CNS immune privilege. In: JOURNAL OF IMMUNOLOGY. 2020.
Sampson JH, Gunn MD, Fecci PE, Ashley DM. Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer. 2020 Jan;20(1):12–25.
Lorrey SJ, Chongsathidkiet P, Wilkinson DS, Champion C, Fecci P. Intracranial tumors lead to sequestration of T cells in the bone marrow. In: JOURNAL OF IMMUNOLOGY. 2020.
Srinivasan E, Sankey E, Grabowski M, Griffin A, Howell E, Otvos B, et al. RADIOGRAPHIC CHARACTERISTICS AND STEROID USAGE IN LASER INTERSTITIAL THERMAL THERAPY VERSUS MEDICAL MANAGEMENT FOR BIOPSY-PROVEN RADIATION NECROSIS AFTER STEREOTACTIC RADIOSURGERY OF BRAIN METASTASES. In: NEURO-ONCOLOGY. 2020. p. 116–7.
Fairchild A, Ramirez L, Adamson J, Floyd SR, Moravan MJJ, Fecci P, et al. Five-Fraction Stereotactic Radiosurgery (SRS) For Resected Brain Metastases. In: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2020. p. E706–7.
Ryan K, Wilkinson D, Landi D, Fecci P. GENERATION OF A HIGH-AFFINITY EGFR/EGFRVIII-TARGETED D2C7 CAR-T CELL. In: NEURO-ONCOLOGY. 2020. p. 65–6.
Torok JA, Floyd SR, Fecci PE, Kirkpatrick JP. Hypofractionated Stereotactic Radiosurgery (HF-SRS) in the Treatment of Brain Metastases. In: Central Nervous System Metastases: Diagnosis and Treatment. 2020. p. 329–41.
Mohammadi AM, Sharma M, Beaumont TL, Juarez KO, Kemeny H, Dechant C, et al. Upfront Magnetic Resonance Imaging-Guided Stereotactic Laser-Ablation in Newly Diagnosed Glioblastoma: A Multicenter Review of Survival Outcomes Compared to a Matched Cohort of Biopsy-Only Patients. Neurosurgery. 2019 Dec 1;85(6):762–72.
Kirkpatrick JP, Fecci PE. Offer Hypofractionated SRS… If Her Performance Status Is Good. Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):940–1.
Fecci PE, Champion CD, Hoj J, McKernan CM, Goodwin CR, Kirkpatrick JP, et al. The Evolving Modern Management of Brain Metastasis. Clin Cancer Res. 2019 Nov 15;25(22):6570–80.
Hodges SE, Yang Z, Charalambous L, Adil SM, Kiyani M, Musick A, et al. HEALTHCARE RESOURCE UTILIZATION OF LEPTOMENINGEAL CARCINOMATOSIS IN THE UNITED STATES. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2019. p. 117–8.
Marius C, Ripple K, de Castro G, Chen Y, Giamberadino C, Verbick L, et al. ENHANCED DRUG DELIVERY AND CIRCULATION WITH THE NEURAPHERESIST SYSTEM FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2019. p. 86–7.
Sankey EW, Tsvankin V, Grabowski MM, Nayar G, Batich KA, Risman A, et al. Operative and peri-operative considerations in the management of brain metastasis. Cancer Med. 2019 Nov;8(16):6809–31.
Liu Y, Chongsathidkiet P, Crawford BM, Odion R, Dechant CA, Kemeny HR, et al. Plasmonic gold nanostar-mediated photothermal immunotherapy for brain tumor ablation and immunologic memory. Immunotherapy. 2019 Oct;11(15):1293–302.
Fairchild A, Torok JA, Adamson J, Floyd SR, Moravan MJ, Fecci P, et al. Postoperative Five-Fraction Radiosurgery for Resected Brain Metastases. In: International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2019. p. E74–5.
Lorrey SJ, Sanchez-Perez L, Fecci PE. Rescuing imperfect antigens for immuno-oncology. Nat Biotechnol. 2019 Sep;37(9):1002–3.
Fecci PE, Sampson JH. The current state of immunotherapy for gliomas: an eye toward the future. J Neurosurg. 2019 Sep 1;131(3):657–66.
Choi KJ, Ackall FY, Truong T, Cheng TZ, Kuchibhatla M, Zomorodi AR, et al. Sinonasal Quality of Life Outcomes After Extended Endonasal Approaches to the Skull Base. J Neurol Surg B Skull Base. 2019 Aug;80(4):416–23.
DeChant C, Chongsathidkiet P, Wilkinson D, Wang H, Kemeny H, Polania JW, et al. Lymphopenia and Bone Marrow T-cell Sequestration Accompanying Stroke are Mediated by T-cell S1P1 Loss. In: JOURNAL OF NEUROSURGERY. AMER ASSOC NEUROLOGICAL SURGEONS; 2019.
Woroniecka K, Dechant C, Rhodin K, Chongsathidkiet P, Wilkerson D, Cui X, et al. Targeting Immunostimulatory Pathways in Combination with Checkpoint Blockade Improves Survival in Murine Glioma. In: JOURNAL OF NEUROSURGERY. AMER ASSOC NEUROLOGICAL SURGEONS; 2019.
Woroniecka K, Dechant C, Rhodin K, Chongsathidkiet P, Wilkinson D, Cui X, et al. Fostering Antecedent T-cell Activation with 41BB Agonism Licenses Checkpoint Blockade in Murine Glioma. In: JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY. OXFORD UNIV PRESS INC; 2019. p. 529–529.
Wilkinson DS, Chongsathidkiet P, Dechant C, Fecci P. Sphingosine-1-phosphate receptor 1 (S1P1) loss mediates T cell sequestration in bone marrow in the setting of intracranial tumors: a novel mode of cancer-induced immunosuppression. In: JOURNAL OF IMMUNOLOGY. AMER ASSOC IMMUNOLOGISTS; 2019.
Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, et al. Author Correction: Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. 2019 Mar;25(3):529.
Tucker MB, Joseph S, Ross W, Ma G, Chongsathidkiet P, Fecci P, et al. Creation of a non-contact, automated brain tumor detection device for use in brain tumor resection. In: Progress in Biomedical Optics and Imaging - Proceedings of SPIE. 2019.
Natarajan BD, Rushing CN, Cummings MA, Jutzy JM, Choudhury KR, Moravan MJ, et al. Predicting intracranial progression following stereotactic radiosurgery for brain metastases: Implications for post SRS imaging. J Radiosurg SBRT. 2019;6(3):179–87.
Chongsathidkiet P, Dechant C, Wilkinson D, Wang H, Kemeny H, Cui X, et al. Bone Marrow T-Cell Sequestration and Lymphopenia Accompanying Ischemic Stroke are Mediated by T-Cell S1P1 Loss. In: NEUROSURGERY. 2019. p. 51–2.
Suryadevara CM, Desai R, Farber SH, Choi BD, Swartz AM, Shen SH, et al. Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts. Clin Cancer Res. 2019 Jan 1;25(1):358–68.
Tanksley J, Adamson J, Torok J, Kim GJ, Floyd SR, Fecci P, et al. Surgical Cavities Exhibit Substantial Remodeling Post Resection of Brain Metastases: Implications for Stereotactic Radiosurgery (SRS). In: International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2018. p. S151–S151.
Chongsathidkiet P, Liu Y, Kemeny H, Dechant C, Odion R, Cui X, et al. A NOVEL NANOTECHNOLOGY-BASED PLATFORM IMPROVES LASER INTERSTITIAL THERMAL THERAPY FOR INTRACRANIAL TUMORS. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2018. p. 89–90.
Chongsathidkiet P, Woroniecka K, Dechant C, Kemeny H, Cui X, Wilkinson D, et al. PREVENTING T-CELL S1P1 INTERNALIZATION OBVIATES BONE MARROW T CELL SEQUESTRATION AND IMPROVES IMMUNOTHERAPEUTIC EFFICACY IN GBM. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2018. p. 127–127.
Kamath A, Tatter S, Fecci P, Chen C, Chiang V, Rao G, et al. LASER ABLATION FOR BRAIN METASTASES: SAFETY AND PRELIMINARY OUTCOMES FROM THE LASER ABLATION OF ABNORMAL NEUROLOGICAL TISSUE USING ROBOTIC NEUROBLATE SYSTEM (LAANTERN) REGISTRY. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2018. p. 251–251.
Mohammadi A, Sharma M, Beaumont T, Juarez K, Kemeny H, Dechant C, et al. UPFRONT MRI-GUIDED STEREOTACTIC LASER-ABLATION IN NEWLY DIAGNOSED GLIOBLASTOMA: A MULTICENTER REVIEW OF SURVIVAL OUTCOMES COMPARED TO A MATCHED COHORT OF BIOPSY-ONLY PATIENTS. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2018. p. 253–4.
Woroniecka K, Fecci PE. T-cell exhaustion in glioblastoma. Oncotarget. 2018 Oct 19;9(82):35287–8.
Atik AF, Suryadevara CM, Schweller RM, West JL, Healy P, Herndon Ii JE, et al. Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells. J Clin Neurosci. 2018 Oct;56:163–8.
Kamath AA, Kim AH, Chen CC, Tatter SB, Fecci P, Toyota B, et al. 304 Safety of Laser Ablation for Brain Tumors. In: Neurosurgery. Ovid Technologies (Wolters Kluwer Health); 2018. p. 123–4.
Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. 2018 Sep;24(9):1459–68.
Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, et al. T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. Clin Cancer Res. 2018 Sep 1;24(17):4175–86.
Kemeny H, Elsamadicy AA, Farber SH, Chongsathidkiet P, Dechant C, Shen S, et al. 301 Antitumor Efficacy of Anti-PDL-1 In ACTH-Secreting Pituitary Adenomas. In: Neurosurgery. Ovid Technologies (Wolters Kluwer Health); 2018. p. 122–3.
Woroniecka KI, Rhodin KE, Chongsathidkiet P, Keith KA, Fecci PE. T-cell Dysfunction in Glioblastoma: Applying a New Framework. Clin Cancer Res. 2018 Aug 15;24(16):3792–802.
Rennert RC, Khan U, Tatter SB, Field M, Toyota B, Fecci PE, et al. Patterns of Clinical Use of Stereotactic Laser Ablation: Analysis of a Multicenter Prospective Registry. World Neurosurg. 2018 Aug;116:e566–70.
Giles AJ, Hutchinson M-KND, Sonnemann HM, Jung J, Fecci PE, Ratnam NM, et al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018 Jun 11;6(1):51.
Oldham M, Yoon SW, Adamson J, Zhang X, Fecci P, Dewhirst M. In Reply to Pratx and Kapp. Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):495–6.
Chongsathidkiet P, Kemeny H, Liu Y, Elsamadicy A, Cui X, Woroniecka K, et al. SYMPHONY: A novel synergistic nanotechnology-based platform for the improvement of laser interstitial thermal therapy. In: JOURNAL OF NEUROSURGERY. AMER ASSOC NEUROLOGICAL SURGEONS; 2018. p. 60–60.
Kemeny H, Elsamadicy A, Farber S, Chongsathidkiet P, Woroniecka K, Cui X, et al. Antitumor efficacy Of anti-PDL-1 In ACTH-secreting pituitary adenomas: an immunotherapeutic approach for Cushing's disease. In: JOURNAL OF NEUROSURGERY. AMER ASSOC NEUROLOGICAL SURGEONS; 2018. p. 81–2.
Yoon SW, Tsvankin V, Shrock Z, Meng B, Zhang X, Dewhirst M, et al. Enhancing Radiation Therapy Through Cherenkov Light-Activated Phototherapy. Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):794–801.
Riccione KA, He L-Z, Fecci PE, Norberg PK, Suryadevara CM, Swartz A, et al. CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response. Oncoimmunology. 2018;7(12):e1502904.
Reap EA, Suryadevara CM, Batich KA, Sanchez-Perez L, Archer GE, Schmittling RJ, et al. Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. Cancer Res. 2018 Jan 1;78(1):256–64.
Woroniecka K, Chongsathidkiet P, Elsamadicy A, Farber H, Cui X, Fecci PE. Flow Cytometric Identification of Tumor-Infiltrating Lymphocytes from Glioblastoma. Methods Mol Biol. 2018;1741:221–6.
Suryadevara CM, Desai R, Abel ML, Riccione KA, Batich KA, Shen SH, et al. Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. Oncoimmunology. 2018;7(6):e1434464.
Babi M-A, Fecci P, Luedke M, Pineda O, O’Keefe YA. Atypical teratoid rhabdoid tumor in a 65-year-old man presenting with disseminated leptomeningeal disease: A case report and review of the literature. SAGE Open Med Case Rep. 2018;6:2050313X18775298.
Elsamadicy AA, Farber SH, Chongsathidkiet P, Kemeny H, Woroniecka K, Cui X, et al. ANTITUMOR EFFICACY OF ANTI-PDL1 IN ACTH-SECRETING PITUITARY ADENOMAS: AN IMMUNOTHERAPEUTIC APPROACH FOR CUSHING'S DISEASE. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2017. p. 264–5.
Narloch JL, Farber SH, Sammons S, McSherry F, Herndon JE, Hoang JK, et al. Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis. Neuro Oncol. 2017 Oct 1;19(10):1391–7.
Oldham M, Yoon SW, Adamson J, Shrock Z, Tsvankin V, Fecci P, et al. Enhancing Radiation Therapy Through Cherenkov Light-Activated Phototherapy from Clinical Megavoltage Treatment Beams. In: International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2017. p. S229–30.
Nayar G, Ejikeme T, Chongsathidkiet P, Elsamadicy AA, Blackwell KL, Clarke JM, et al. Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget. 2017 Sep 22;8(42):73312–28.
Chen CC, Rennert R, Khan U, Tatter SB, Field M, Toyota B, et al. 372 Evolving Patterns in Clinical Utilization of Stereotactic Laser Ablation (SLA). In: Neurosurgery. Ovid Technologies (Wolters Kluwer Health); 2017. p. 287–8.
Chen CC, Rennert R, Khan U, Tatter SB, Field M, Toyota B, et al. 223 Procedural Safety of Stereotactic Laser Ablation (SLA) and Associated Hospital Stay. In: Neurosurgery. Ovid Technologies (Wolters Kluwer Health); 2017. p. 261–261.
Yoon S, Tsvankin V, Shrock Z, Meng B, Dewhirst M, Fecci P, et al. A Novel Method to Enhance Standard of Care Radiation Therapy: Cherenkov Light Activated Psoralen (CLAP). In: MEDICAL PHYSICS. WILEY; 2017. p. 2995–6.
Narloch J, Luedke C, Broadwater G, Priedigkeit N, Hall A, Hyslop T, et al. Number of tumor-infiltrating lymphocytes in breast cancer brain metastases compared to matched breast primaries. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017. p. 2049–2049.
Elsamadicy AA, Chongsathidkiet P, Desai R, Woroniecka K, Farber SH, Fecci PE, et al. Prospect of rindopepimut in the treatment of glioblastoma. Expert Opin Biol Ther. 2017 Apr;17(4):507–13.
Elsamadicy AA, Farber H, Chongsathidkiet P, Woroniecka K, Cui X, Dunn I, et al. Expression of PDL-1 on Pituitary Adenomas: A Role for Immunotherapy. In: JOURNAL OF NEUROSURGERY. AMER ASSOC NEUROLOGICAL SURGEONS; 2017. p. A1401–A1401.
Suryadevara C, Chongsathidkiet P, Desai R, Abel M, Elsamadicy A, Woroniecka K, et al. Host Lymphopenia Enhances the Abundance, Activation Status, and Antitumor Efficacy of Tumor-specific T Cells Delivered Directly into the Brain. In: JOURNAL OF NEUROSURGERY. AMER ASSOC NEUROLOGICAL SURGEONS; 2017. p. A1443–A1443.
Chongsathidkiet P, Farber S, Woroniecka K, Elsamadicy A, Cui X, Fecci P. Downregulation of sphingosine-1-phosphate receptor type 1 mediates T-cell sequestration in bone marrow amidst glioblastoma. In: JOURNAL OF NEUROSURGERY. AMER ASSOC NEUROLOGICAL SURGEONS; 2017. p. A1442–A1442.
Berry-Candelario J, Farber SH, Fecci PE. Immune Constitution of Patients with Brain Tumors. In: Translational Immunotherapy of Brain Tumors. 2017. p. 13–32.
Farber SH, Elsamadicy AA, Atik AF, Suryadevara CM, Chongsathidkiet P, Fecci PE, et al. The Safety of available immunotherapy for the treatment of glioblastoma. Expert Opin Drug Saf. 2017 Mar;16(3):277–87.
Narloch JL, Harnden K, Broadwater G, Peterson B, Hyslop T, Kirkpatrick J, et al. Abstract P5-08-12: HER2 status remains the primary predictor of improved survival in patients with BCBM over the past 2 decades (1996-2015). In: Cancer Research. American Association for Cancer Research (AACR); 2017.
Limon D, McSherry F, Herndon J, Sampson J, Fecci P, Adamson J, et al. Single fraction stereotactic radiosurgery for multiple brain metastases. Adv Radiat Oncol. 2017;2(4):555–63.
Mei Y, Bi WL, Greenwald NF, Du Z, Agar NYR, Kaiser UB, et al. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget. 2016 Nov 22;7(47):76565–76.
Suryadevara CM, Desai R, Snyder DJ, Li Q-J, Fecci PE, Sanchez-Perez L, et al. LYMPHOPENIA ENHANCES THE EFFICACY OF CAR T CELLS DELIVERED LOCO-REGIONALLY IN THE BRAIN FOR THE TREATMENT OF GLIOBLASTOMA. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2016. p. 96–96.
Suryadevara CM, Chongsathidkiet P, Riccione K, Gedeon PC, Desai R, Choi BD, et al. CAR T CELLS INDUCE COMPLETE REGRESSION OF MURINE GLIOBLASTOMA AFTER PRECONDITIONING HOSTS WITH TEMOZOLOMIDE. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2016. p. 94–5.
Chongsathidkiet P, Farber SH, Woroniecka K, Elsamadicy AA, Cui X, Fecci P. DOWNREGULATION OF SPHINGOSINE-1-PHOSPHATE RECEPTOR TYPE 1 MEDIATES BONE MARROW T-CELL SEQUESTRATION IN PATIENTS AND MICE WITH GLIOBLASTOMA. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2016. p. 88–88.
Elsamadicy AA, Farber SH, Chongsathidkiet P, Woroniecka K, Cui X, Fecci P. EXPRESSION OF PDL-1 ON PITUITARY ADENOMAS: A ROLE FOR IMMUNOTHERAPY. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2016. p. 87–87.
Woroniecka K, Farber SH, Chongsathidkiet P, Elsamadicy AA, Cui X, Fecci P. T CELL EXHAUSTION IN PATIENTS AND MICE WITH GBM. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2016. p. 93–93.
Limon D, Kim GJ, McSherry F, Herndon J, Fecci PE, Adamson J, et al. Single-Fraction Radiosurgery for 4 or More Brain Metastases. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E84–5.
Suryadevara CM, Desai R, Farber SH, Gedeon PC, Swartz A, Snyder D, et al. 369 Chimeric Antigen Receptors Deficient in Lck Signaling Require 4-1BB Costimulation to Expand in Vivo, Resist Regulatory T-Cell Suppression, and Treat Solid Tumors in Immune-Intact Hosts. Neurosurgery. 2016 Aug 1;63(CN_suppl_1):209–10.
Suryadevara CM, Desai R, Farber SH, Gedeon PC, Swartz A, Snyder D, et al. 369 Chimeric Antigen Receptors Deficient in Lck Signaling Require 4-1BB Costimulation to Expand in Vivo, Resist Regulatory T-Cell Suppression, and Treat Solid Tumors in Immune-Intact Hosts. Neurosurgery. 2016 Aug;63 Suppl 1:209–10.
Farber SH, Tsvankin V, Narloch JL, Kim GJ, Salama AKS, Vlahovic G, et al. Embracing rejection: Immunologic trends in brain metastasis. Oncoimmunology. 2016 Jul;5(7):e1172153.
Oldham M, Yoon S, Meng B, Fathi Z, Beyer W, Adamson J, et al. WE-FG-BRA-01: Cancer Treatment Utilizing Photo-Activation of Psoralen with KV X-Rays. Med Phys. 2016 Jun;43(6):3823.
Fecci PE, Riccione K, Dunn GP, Reap E, Vlahovic G, Congdon K, et al. Immunotherapy for gliomas. In: The Duke Glioma Handbook: Pathology, Diagnosis, and Management. 2016. p. 91–120.
Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, et al. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 2016 Mar 1;76(5):999–1008.
Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016 Feb 17;7:10501.
Oldham M, Yoon P, Fathi Z, Beyer WF, Adamson J, Liu L, et al. X-Ray Psoralen Activated Cancer Therapy (X-PACT). PLoS One. 2016;11(9):e0162078.
Kim GJ, Barkdoll T, Sampson JH, Wang Z, Hoang J, Fecci PE, et al. Pathologic Evaluation of Radiographically Enlarging Lesions After Stereotactic Radiosurgery for Brain Metastases. In: International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2015. p. E93–E93.
Choi BD, Fecci PE, Sampson JH. Editorial: Not everything that matters can be measured and not everything that can be measured matters. J Neurosurg. 2015 Sep;123(3):543–4.
Vlahovic G, Fecci PE, Reardon D, Sampson JH. Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma. Neuro Oncol. 2015 Aug;17(8):1043–5.
Swartz AM, Batich KA, Fecci PE, Sampson JH. Peptide vaccines for the treatment of glioblastoma. J Neurooncol. 2015 Jul;123(3):433–40.
Fecci PE, Babu R, Adamson DC, Sampson JH. Editorial: Turning fluorescence into black and white. J Neurosurg. 2015 Jun;122(6):1356–8.
Suryadevara CM, Gedeon PC, Sanchez-Perez L, Verla T, Alvarez-Breckenridge C, Choi BD, et al. Are BiTEs the "missing link" in cancer therapy? Oncoimmunology. 2015 Jun;4(6):e1008339.
Suryadevara CM, Verla T, Sanchez-Perez L, Reap EA, Choi BD, Fecci PE, et al. Immunotherapy for malignant glioma. Surg Neurol Int. 2015;6(Suppl 1):S68–77.
Choi BD, Fecci PE, Sampson JH. Immunobiology and Immune Therapy. In: NEURO-ONCOLOGY: THE ESSENTIALS, 3RD EDITION. 2015. p. 254–63.
Fecci PE, Chen C, Baumeister S, Dranoff G. Cancer Immunotherapy: The Road to Rejection. In: ADVANCED VACCINE RESEARCH: METHODS FOR THE DECADE OF VACCINES. 2015. p. 359–85.
Fecci PE, Heimberger AB, Sampson JH. Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res. 2014 Nov 15;20(22):5620–9.
Yanamadala V, Walcott BP, Fecci PE, Rozman P, Kumar JI, Nahed BV, et al. Reversal of warfarin associated coagulopathy with 4-factor prothrombin complex concentrate in traumatic brain injury and intracranial hemorrhage. J Clin Neurosci. 2014 Nov;21(11):1881–4.
Gedeon PC, Riccione KA, Fecci PE, Sampson JH. Antibody-based immunotherapy for malignant glioma. Semin Oncol. 2014 Aug;41(4):496–510.
Cheema TA, Fecci PE, Ning J, Rabkin SD. Immunovirotherapy for the treatment of glioblastoma. Oncoimmunology. 2014 Jan 1;3(1):e27218.
Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013 Dec;3(12):1355–63.
Fecci PE, Koyama S, Chen C, Cheema T, Dranoff G, Martuza R, et al. Lost And Found: Therapeutic Implications Of Bone Marrow As Harbor For Missing T-Cells In Glioma. In: JOURNAL OF NEUROSURGERY. AMER ASSOC NEUROLOGICAL SURGEONS; 2013. p. A564–A564.
Fecci P, Chen C, Koyama S, Dranoff G, Martuza RL, Curry WT. 198 Of Mice and Men. In: Neurosurgery. Ovid Technologies (Wolters Kluwer Health); 2013. p. 185–6.
Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS, et al. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):12006–11.
Reardon DA, Wucherpfennig KW, Freeman G, Wu CJ, Chiocca EA, Wen PY, et al. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013 Jun;12(6):597–615.
Choi BD, Fecci PE, Sampson JH. Regulatory T cells move in when gliomas say "I Do". Clin Cancer Res. 2012 Nov 15;18(22):6086–8.
Dunn GP, Fecci PE, Curry WT. Cancer immunoediting in malignant glioma. Neurosurgery. 2012 Aug;71(2):201–22.
Agarwalla P, Barnard Z, Fecci P, Dranoff G, Curry WT. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother. 2012 Jun;35(5):385–9.
Chatterjee N, Domoto-Reilly K, Fecci PE, Schwamm LH, Singhal AB. Licorice-associated reversible cerebral vasoconstriction with PRES. Neurology. 2010 Nov 23;75(21):1939–41.
Hahn B, Fecci A, Jacobs C. Renal artery aneurysm. J Emerg Med. 2010 Jun;38(5):654–5.
Curry WT, Barnard ZR, Agarwalla PK, Fecci P, Dranoff G. CTLA-4 BLOCKADE AUGMENTS VACCINE-INDUCED ANTITUMOR IMMUNITY AGAINST INTRACRANIAL GLIOMA. In: NEURO-ONCOLOGY. DUKE UNIV PRESS; 2009. p. 618–618.
Selznick LA, Shamji MF, Fecci P, Gromeier M, Friedman AH, Sampson J. Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines. Neurosurg Rev. 2008 Apr;31(2):141–55.
Mitchell DA, Fecci PE, Sampson JH. Immunotherapy of malignant brain tumors. Immunol Rev. 2008 Apr;222:70–100.
Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res. 2007 Apr 1;13(7):2158–67.
Learn CA, Fecci PE, Schmittling RJ, Xie W, Karikari I, Mitchell DA, et al. Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. Clin Cancer Res. 2006 Dec 15;12(24):7306–15.
Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, Mitchell DA, et al. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4294–305.
Unger JM, Fecci P, Ochiai H, Mitchell DA, Schmittling R, Chewning TA, et al. Radiotherapy with regulatory T-cell depletion is synergistic for treatment of experimental model of malignant glioma. In: JOURNAL OF NEUROSURGERY. AMER ASSOC NEUROLOGICAL SURGEONS; 2006. p. A637–8.
Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006 Mar 15;66(6):3294–302.
Learn CA, Schmittling RJ, Fecci PE, Mitchell DA, Archer GE, Sampson JH. Expression profiling of CD4+ and CD8+ T cells in malignant glioma. In: CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 2005. p. 8999S-8999S.
Mitchell DA, Fecci PE, Sampson JH. Adoptive immunotherapy for malignant glioma. Cancer J. 2003;9(3):157–66.
Fecci PE, Mitchell DA, Archer GE, Morse MA, Lyerly HK, Bigner DD, et al. The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J Neurooncol. 2003;64(1–2):161–76.
Fecci PE, Sampson JH. Clinical immunotherapy for brain tumors. Neuroimaging Clin N Am. 2002 Nov;12(4):641–64.
Fecci PE, Gromeier M, Sampson JH. Viruses in the treatment of brain tumors. Neuroimaging Clin N Am. 2002 Nov;12(4):553–70.
Desjardins A, Randazzo D, Chandramohan V, Peters KB, Johnson MO, Threatt S, et al. Dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for recurrent malignant glioma. In.
Desjardins A, Randazzo D, Chandramohan V, Peters K, Johnson MO, Threatt S, et al. Dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for recurrent malignant glioma. In.

In The News

When Cancer Spreads to the Brain and Spine (Aug 29, 2022 | School of Medicine)
Searching for A Higher Gear in the Fight Against Brain Cancer (Dec 2, 2021 | The Graduate School)
Cohen-Wolkowiez, Fecci, and Herman Elected Members of American Society for Clinical Investigation (May 5, 2021 | School of Medicine )
A Duke Team Just Found Missing Immune Cells That Could Fight Lethal Brain Tumors (Aug 13, 2018 | Duke Health News)
Duke neurosurgeon: Many factors in McCain's favor as he undergoes cancer treatment (Jul 20, 2017 | )